IMMUNOMEDICS INC
Healthcare · In Vitro & In Vivo Diagnostic Substances · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $482,000 | $3.1M | $899,000 | $5.7M | $9.0M |
| Operating income | −$324.8M | −$141.0M | −$79.1M | −$59.0M | −$46.2M | −$35.6M |
| Net income | −$87.3M | −$35.5M | −$59.3M | −$14.0M | −$48.0M | −$35.4M |
| Total assets | $671.7M | $528.0M | $162.6M | $57.0M | $105.8M | $47.5M |
| Total liabilities | $404.5M | $262.2M | $222.0M | — | — | — |
| Equity | $268.3M | $266.8M | −$58.7M | −$56.8M | −$3.9M | $39.3M |
| EPS (diluted) | — | — | — | — | — | $-0.42 |
| Shares out. | 212.4M | 186.8M | 111.3M | 95.9M | 94.6M | 93.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2019- Operating margin
- —
- Net margin
- —
- Return on equity
- −32.6%
- Return on assets
- −13.0%
- Return on capital (ROCE)
- −54.1%
- Liabilities / assets
- 60.2%
- Debt / equity
- 1.51×
- Book value / share
- $1.26
- Revenue growth (YoY)
- −100.0%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2019- Altman Z″ (distress)
- -3.38distress
- Accruals / assets
- 20.1%high accruals
- Piotroski F-Score
- 0/8weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 3 warning● 0 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Revenue declined year-over-year
- Negative operating cash flow
- High accruals — earnings-quality risk
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Feb 10, 2006
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Aghazadeh BehzadDirector | Oct 23, 2020 | D | 13,516 | — |
| Malik UsamaOfficer — Chief Fin. & Business Officer | Oct 23, 2020 | D | 18,856 | — |
| Canute Scott ADirector | Oct 23, 2020 | D | 13,516 | — |
| Hutt Peter BartonDirector | Oct 23, 2020 | D | 13,516 | — |
| Itri Lorettta MOfficer — Chief Medical Officer | Oct 23, 2020 | D | 15,000 | — |
| Islam KhalidDirector | Oct 23, 2020 | D | 13,516 | — |
| Ball BryanOfficer — Chief Quality Officer | Oct 23, 2020 | D | 10,000 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsOct 23, 2020
- Other material eventSep 21, 2020
- Director / officer changeSep 17, 2020
- Entered a material agreement · Other material eventSep 14, 2020
- Other material eventAug 17, 2020
- Results of operations · Other material eventAug 5, 2020
- Other material eventJul 6, 2020
- Director / officer change · Amended charter or bylaws · Shareholder voteJun 18, 2020
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.